Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Immunologic Research
Published in: Immunologic Research 1-3/2009

01-07-2009

Mutations of the Wiskott–Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes

Author: Hans D. Ochs

Published in: Immunologic Research | Issue 1-3/2009

Login to get access

Abstract

Mutations of the Wiskott–Aldrich Syndrome Protein (WASP) are responsible for classic Wiskott–Aldrich Syndrome (WAS), X-linked thrombocytopenia (XLT), and in rare instances congenital X-linked neutropenia (XLN). WASP is a regulator of actin polymerization in hematopoietic cells with well-defined functional domains that are involved in cell signaling and cell locomotion, immune synapse formation, and apoptosis. Mutations of WASP are located throughout the gene and either inhibit or disregulate normal WASP function. Analysis of a large patient population demonstrates a strong phenotype–genotype correlation. Classic WAS occurs when WASP is absent, XLT when mutated WASP is expressed and XLN when missense mutations occur in the Cdc42-binding site. However, because there are exceptions to this rule it is difficult to predict the long-term prognosis of a given affected boy solely based on the analysis of WASP expression.
Literature
1.
Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott–Aldrich Syndrome. Cell. 1994;78:635–44.PubMedCrossRef
2.
Wiskott A. Familiärer, angeborener Morbus Werihofii? Monastsschr Kinderheilkd. 1937;68:212–6.
3.
Aldrich R, Steinberg A, Campbell D. Pedigree demonstrating a sex-linked recessive condition characterized by draining ears, eczematoid dermatits and bloody diarrhea. Pediatrics. 1954;13:133–9.PubMed
4.
Blaese RM, Strober W, Brown RS, et al. The Wiskott–Aldrich Syndrome. A disorder with a possible defect in antigen processing or recognition. Lancet. 1968;1:1056–61.PubMed
5.
Cooper MD, Chae HP, Lowman JT, et al. Wiskott–Aldrich Syndrome. An immunologic deficiency disease involving the afferent limb of immunity. Am J Med. 1968;44:499–513.PubMedCrossRef
6.
Ochs HD, Slichter SJ, Harker LA, et al. The Wiskott–Aldrich Syndrome: studies of lymphocytes, granulocytes, and platelets. Blood. 1980;55:243–52.PubMed
7.
Sullivan KE, Mullen CA, Blaese RM, et al. A multiinstitutional survey of the Wiskott–Aldrich Syndrome. J Pediatr. 1994;125:876–85.PubMedCrossRef
8.
Molina IJ, Sancho J, Terhorst C, et al. T cells of patients with the Wiskott–Aldrich Syndrome have a restricted defect in proliferative responses. J Immunol. 1993;151:4383–90.PubMed
9.
Gallego MD, Santamaria M, Pena J, et al. Defective actin reorganization and polymerization of Wiskott–Aldrich T cells in response to CD3-mediated stimulation. Blood. 1997;90:3089–97.PubMed
10.
Park JY, Shcherbina A, Rosen FS, et al. Phenotypic perturbation of B cells in the Wiskott–Aldrich Syndrome. Clin Exp Immunol. 2005;139:297–305.PubMedCrossRef
11.
Westerberg L, Larsson M, Hardy SJ, et al. Wiskott–Aldrich Syndrome Protein deficiency leads to reduced B-cell adhesion, migration, and homing, and a delayed humoral immune response. Blood. 2005;105:1144–52.PubMedCrossRef
12.
Westerberg LS, de la Fuente MA, Wermeling F, et al. WASP Confers selective advantage for specific hematopoietic cell populations and serves a unique role in marginal zone B cell homeostasis and function. Blood. 2008;112:4139–47.PubMedCrossRef
13.
Meyer-Bahlburg A, Becker-Herman S, Humblet-Baron S, et al. Wiskott–Aldrich Syndrome Protein deficiency in B cells results in impaired peripheral homeostasis. Blood. 2008;112:4158–69.PubMedCrossRef
14.
Orange JS, Ramesh N, Remold-O’Donnell E, et al. Wiskott–Aldrich Syndrome Protein is required for NK cell cytotoxicity and colocalizes with actin to NK cell-activating immunologic synapses. Proc Natl Acad Sci USA. 2002;99:11351–6.PubMedCrossRef
15.
Gismondi A, Cifaldi L, Mazza C, et al. Impaired natural and CD16-mediated NK cell cytotoxicity in patients with WAS and XLT: ability of IL-2 to correct NK cell functional defect. Blood. 2004;104:436–43.PubMedCrossRef
16.
Huang W, Ochs HD, Dupont B, et al. The Wiskott–Aldrich Syndrome Protein regulates nuclear translocation of NFAT2 and NF-kappa B (RelA) independently of its role in filamentous actin polymerization and actin cytoskeletal rearrangement. J Immunol. 2005;174:2602–11.PubMed
17.
Badolato R, Sozzani S, Malacarne F, et al. Monocytes from Wiskott–Aldrich patients display reduced chemotaxis and lack of cell polarization in response to monocyte chemoattractant protein–1 and formyl-methionyl-leucyl-phenylalanine. J Immunol. 1998;161:1026–33.PubMed
18.
Binks M, Jones GE, Brickell PM, et al. Intrinsic dendritic cell abnormalities in Wiskott–Aldrich Syndrome. Eur J Immunol. 1998;28:3259–67.PubMedCrossRef
19.
de Noronha S, Hardy S, Sinclair J, et al. Impaired dendritic-cell homing in vivo in the absence of Wiskott–Aldrich Syndrome Protein. Blood. 2005;105:1590–7.PubMedCrossRef
20.
Humblet-Baron S, Sather B, Anover S, et al. Wiskott–Aldrich Syndrome Protein is required for regulatory T cell homeostasis. J Clin Invest. 2007;117:407–18.PubMedCrossRef
21.
Dupuis-Girod S, Medioni J, Haddad E, et al. Autoimmunity in Wiskott–Aldrich Syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients. Pediatrics. 2003;111:622–7.CrossRef
22.
Welch MD, Mullins RD. Cellular control of actin nucleation. Annu Rev Cell Dev Biol. 2002;18:247–88.PubMedCrossRef
23.
Badour K, Zhang J, Shi F, et al. The Wiskott–Aldrich Syndrome Protein acts downstream of CD2 and the CD2AP and PSTPIP1 adaptors to promote formation of the immunological synapse. Immunity. 2003;18:141–54.PubMedCrossRef
24.
Sasahara Y, Rachid R, Byrne MJ, et al. Mechanism of recruitment of WASP to the immunological synapse and of its activation following TCR ligation. Mol Cell. 2002;10:1269–81.PubMedCrossRef
25.
Volkman BF, Prehoda KE, Scott JA, et al. Structure of the N-WASP EVH1 domain-WIP complex: insight into the molecular basis of Wiskott–Aldrich Syndrome. Cell. 2002;111:565–76.PubMedCrossRef
26.
27.
Rudolph MG, Bayer P, Abo A, et al. The Cdc42/Rac interactive binding region motif of the Wiskott Aldrich Syndrome Protein (WASP) is necessary but not sufficient for tight binding to Cdc42 and structure formation. J Biol Chem. 1998;273:18067–76.PubMedCrossRef
28.
Kim AS, Kakalis LT, Abdul-Manan N, et al. Autoinhibition and activation mechanisms of the Wiskott–Aldrich Syndrome Protein. Nature. 2000;404:151–8.PubMedCrossRef
29.
Notarangelo LD, Mazza C, Giliani S, et al. Missense mutations of the WASP gene cause intermittent X-linked thrombocytopenia. Blood. 2002;99:2268–9.PubMedCrossRef
30.
Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet. 2001;27:313–7.PubMedCrossRef
31.
Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott–Aldrich Syndrome Protein result in congenital neutropenia. Blood. 2006;108:2182–9.PubMedCrossRef
32.
Moulding DA, Blundell MP, Spiller DG, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med. 2007;204:2213–24.PubMedCrossRef
33.
Beel K, Cotter MM, Blatny J, et al. A large kindred with X-linked neutropenia with an I294T mutation of the Wiskott-Aldrich Syndrome gene. Br J Haematol. 2008, Nov 1 [Epub ahead of print].
34.
Ochs HD, Rosen FS. Wiskott–Aldrich Syndrome. In: Ochs HD, Smith CIE, Puck JM, editors. Primary immunodeficiency diseases, a molecular and genetic approach. New York: Oxford University Press; 2007. p. 454–69.
35.
Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott–Aldrich Syndrome Protein (WASP): hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood. 2004;104:4010–9.PubMedCrossRef
36.
Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood. 2004;103:456–64.PubMedCrossRef
Metadata
Title
Mutations of the Wiskott–Aldrich Syndrome Protein affect protein expression and dictate the clinical phenotypes
Author
Hans D. Ochs
Publication date
01-07-2009
Publisher
Humana Press Inc
Published in
Immunologic Research / Issue 1-3/2009
Print ISSN: 0257-277X
Electronic ISSN: 1559-0755
DOI
https://doi.org/10.1007/s12026-008-8084-3

Other articles of this Issue 1-3/2009

Immunologic Research 1-3/2009 Go to the issue

OriginalPaper

Single-center analysis of long-term outcome after hematopoietic cell transplantation in children with congenital severe T cell immunodeficiency

OriginalPaper

Characterization of cultured thymus tissue used for transplantation with emphasis on promiscuous expression of thyroid tissue-specific genes

OriginalPaper

FOXP3 expression following bone marrow transplantation for IPEX syndrome after reduced-intensity conditioning

OriginalPaper

Allogeneic hematopoietic stem cell transplantation for X-linked ectodermal dysplasia and immunodeficiency: case report and review of outcomes

OriginalPaper

Recent advances in the biology of WASP and WIP

OriginalPaper

The thrombocytopenia of WAS: a familial form of ITP?